9903516 - 4 IPOS.

PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K 31/557, 9/00 — A1

(11) International Publication Number: WO 98/41208

(43) International Publication Date: 24 September 1998 (24.09.98)

(21) International Application Number: PCT/EP98/01483

(22) International Filing Date: 13 March 1998 (13.03.98)

(30) Priority Data:
08/819,221 17 March 1997 (17.03.97) US

(71) Applicant *(for all designated States except AT)*: NOVARTIS AG [CH/CH]; Schwarzwaldallee 215, CH–4058 Basel (CH).

(71) Applicant *(for AT only)*: NOVARTIS–ERFINDUNGEN VERWALTUNGSGESELLSCHAFT MBH [AT/AT]; Brunner Strasse 59, A–1235 Vienna (AT).

(72) Inventors: REED, Kenneth, Warren; 1241 Fairfax Hunt, Lawrenceville, GA 30243 (US). YEN, Shau–Fong; 1295 North Druid Hills Road, Atlanta, GA 30319 (US). SOU, Mary; 5665 Bridge Point Drive, Alpharetta, GA 30202 (US). PEACOCK, Regina, Flinn; 11615 Windbrooke Way, Alpharetta, GA 30005 (US).

(74) Agent: BECKER, Konrad; Novartis AG, Patent– und Markenabteilung, Lichtstrasse 35, CH–4002 Basel (CH).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published
With international search report.

(54) **Title:** COMPOSITIONS AND METHODS FOR REDUCING OCULAR HYPERTENSION

(57) **Abstract**

An improved ophthalmic composition, including prostaglandin active agents, which is especially useful in lowering intraocular pressure associated with glaucoma. Improvements in IOP reduction efficacy, preservative efficacy and reduced additive concentrations are achieved by utilizing the disclosed compositions which include a prostaglandin active agent (e.g., isopropyl unoprostone, a metabolite of an F–series prostaglandin), in conjunction with selected non–ionic surfactants, preservatives, and non–ionic tonicity adjusting agents.

THIS SHEET HAS BEEN REPLACED

This Sheet Has Been Replaced